Fundraise

Isomorphic Labs raises $5B to push AI-designed drugs toward trials

What's the deal? Isomorphic Labs has raised $5 billion in Series C funding, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other new investors joining. AlphabetDealroom has a profile for this one. Try Dealroom →, its parent, made a significant investment, and all existing backers — Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund — returned.

Why now? The round comes about six months after Isomorphic raised a $2.1 billion Series B led by Thrive. It also follows chief executive officer Demis Hassabis stepping back as head of Google DeepMind, the lab he co-founded and from which Isomorphic spun out in 2021.

What's the endgame? The London-based company uses AI to design medicines through its proprietary engine, IsoDDE, which predicts drug properties and refines candidates before scientists make and test them. Its internal pipeline spans oncology and immunology. The new funds back further development of IsoDDE and investment in clinical infrastructure.

What's the milestone? Isomorphic is preparing to move its first drug candidates into clinical trials. The company declined to share its valuation.

"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials," Hassabis said.

What could go wrong? Isomorphic has reported only "positive" preclinical results, without detailed data, and has yet to show how IsoDDE-generated candidates perform in humans. Its partnerships with Novartis, Eli Lilly, and Johnson & Johnson add validation but do not prove the approach yields effective medicines.

The signal: The raise reflects record investor appetite for AI drug discovery, a sector that pulled in $23.2 billion in 2026, according to Dealroom. With OpenAI and Anthropic also moving into the field, Isomorphic's rapid back-to-back rounds mark the scale of capital backing a technology whose decisive evidence still lies ahead.

Read more: CNBC, isomorphiclabs.com, fiercebiotech.com, Reuters

Image credit: Generated with Gemini

More top stories